Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.

The Motley Fool • Oct 27, 2026

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 26, 2026

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra® (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

PRNewsWire • Oct 23, 2026

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

PRNewsWire • Oct 19, 2026

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.

Zacks Investment Research • Oct 16, 2026

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gross margins (92.1% non-GAAP), and raised FY guidance to $4.60–$4.75B. Ziihera's FDA approval for 1L HER2-positive GEA marks a major oncology expansion, with clinical data showing a significant survival benefit over standard of care.

Seeking Alpha • Oct 15, 2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Oct 6, 2026

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.

MarketBeat • Sep 20, 2026

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.

MarketBeat • Sep 20, 2026

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.

The Motley Fool • Sep 18, 2026